3 May 2022

In memoriam: Joop Kroes

Elize Brolsma

Elize Brolsma

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.

We received the sad news that Joop Kroes passed away last month. Joop was one of the first patient representatives of Oncode’s Clinical Advisory Board (CAB). He has always been full of enthusiasm for the CAB and Oncode’s Clinical Proof of Concept Programme.

Geert Kops, Head of Oncode Institute, says: “Joop was a very enthusiastic, optimistic and friendly member of the Oncode community. He was a patient representative within the Clinical Advisory Board and was involved since the start of Oncode. He helped set up and shape our Clinical Proof of Concept Programme and reviewed many projects within that programme. He has been living with bowel cancer since 2009 and devoted a lot of his time to the bowel cancer foundation (Stichting Darmkanker). We will miss Joop very much and wish his family and friends a lot of strength in this difficult time.”

Other News

Vidi 12
Vidi Grants awarded to Miao-Ping Chien, Rebekka Schneider, Tineke Lenstra and Monique Mulder
Oncode Institute is proud to announce that three Oncode Investigators and one Oncode Researcher will receive a Vidi Grant worth 800.000 euros. This grant will enable Oncode Investigators Miao-Ping Chien, Rebekka Schneider (both Erasmus MC), Tineke Lenstra (Netherlands Cancer Institute) and Oncode Researcher Monique Mulder (Leiden UMC) to develop their own innovative line of research and set up their own research group in the coming five years.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Banner Wilbert Zwart Lymphnode Universe CMYK
Prostate cancer hijacks tumor cell biorhythm to evade hormone therapy
Hormone therapy is successful at keeping metastatic prostate cancer under control, but eventually the tumor cells become resistant to it. An unexpected potential solution has now emerged in medicines not designed to fight cancer, but to target proteins that regulate a cell’s circadian rhythm. Oncode Investigator Wilbert Zwart and others publish about this discovery in cancer discovery today.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Jeroen de Ridder
Cell-free DNA biomarkers can help to identify treatment responders and non-responders of head and neck cancer patients
The team of Jeroen de Ridder finalized a Clinical Proof of Concept (CPoC) study in which they tested the feasibility of circulating tumor DNA (ctDNA) analysis in head- and neck cancer patients as treatment response identifier. Their results are promising and more extensive validation in larger patient cohorts is underway.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>